$28.56
Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
Overview
52-week range
$0.76
$47
60% of range
Avg surprise (last 2)
+37.3%
Avg reaction (last 2)
-2.6%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.08 | — | — | +60.0% | 0.0% | earnings |
| Thu Aug 14, 2025 | Jun/2025 | $-0.13 | $-0.23 | +43.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.20 | $-0.29 | +31.0% | — | -5.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.29 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.22 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.15 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.01 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.09 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.74 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-4M | — | $-8M | $-9M | — | $-13M | $-10M | $-7M |
| Net income | $-4M | — | $-6M | $-9M | — | $-12M | $-9M | $-6M |
| EPS (diluted) | $-0.08 | — | $-0.13 | $-0.20 | — | $-0.29 | $-0.22 | $-0.15 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $25M | $24M | $22M | $28M | $20M | $16M | $30M | $19M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $26M | $30M | $44M | $55M | $64M | $74M | $84M | $90M |
| Total assets | $26M | $30M | $45M | $56M | $67M | $76M | $87M | $92M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1M | $2M | $6M | $12M | $15M | $13M | $12M | $8M |
| Total equity | $25M | $28M | $39M | $44M | $52M | $64M | $75M | $83M |
Implied volatility — last 90 days
No IV snapshots yet for VYNE.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.